Search Results Search Sort by RelevanceMost Recent Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411. Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411. In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411. Case and Commentary Dec 2004 Preoperative Screening: Medical or Legal Guidelines? Commentary 2 Erin Egan, MD, JD Clinical judgment and experience often trump evidence-based practice guidelines in physicians' medical decision-making process. Virtual Mentor. 2004;6(12):544-546. doi: 10.1001/virtualmentor.2004.6.12.ccas3-0412. State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412. Health Law Apr 2003 Can Patients Contribute to Medical Negligence? Lisa Panique Patients need to be aware that they are fully responsible for disclosing a complete medical history, and physicians may not be liable for damages if they do not comply. Virtual Mentor. 2003;5(4):138-140. doi: 10.1001/virtualmentor.2003.5.4.hlaw1-0304. Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512. Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587. Podcast Jul 2024 Author Interview: "Opioid Epidemic Grief and Characterological Harm Reduction” Dr Christy A. Rentmeester joins Ethics Talk to discuss her article: "Opioid Epidemic Grief and Characterological Harm Reduction.” Pagination First page « First Previous page ‹ Previous … Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Current page 22 Page 23 Page 24 Next page Next › Last page Last »
Medicine and Society Nov 2004 Gatekeeping and the FDA's Role in Human Subjects Protection Daniel Carpenter, PhD The FDA bears the responsibility to monitor clinical trials and protect human subjects from harm. Virtual Mentor. 2004;6(11):512-514. doi: 10.1001/virtualmentor.2004.6.11.msoc1-0411.
Policy Forum Nov 2004 Genetic Samples and Genetic Philanthropy Michael E. Berens, PhD and Gary E. Marchant, PhD, JD Genetic research is threatened by lack of samples, and public policy should be developed to encourage public participation. Virtual Mentor. 2004;6(11):509-511. doi: 10.1001/virtualmentor.2004.6.11.pfor2-0411.
In the Literature Nov 2004 Determining Research through Underdetermined Treatment Abraham P. Schwab, PhD Paul Miller and Charles Weijer defend the concept of equipoise in medical research in a recent journal article. Virtual Mentor. 2004;6(11):488-489. doi: 10.1001/virtualmentor.2004.6.11.jdsc1-0411.
Case and Commentary Dec 2004 Preoperative Screening: Medical or Legal Guidelines? Commentary 2 Erin Egan, MD, JD Clinical judgment and experience often trump evidence-based practice guidelines in physicians' medical decision-making process. Virtual Mentor. 2004;6(12):544-546. doi: 10.1001/virtualmentor.2004.6.12.ccas3-0412.
State of the Art and Science Dec 2004 The Impact of Recent Clinical Trials on National Cholesterol Education Program Adult Treatment Panel III Guidelines Niharika P. Bansal Recent clinical trials have led to updates in the management of patients with high cholesterol. Virtual Mentor. 2004;6(12):550-553. doi: 10.1001/virtualmentor.2004.6.12.cprl1-0412.
Health Law Apr 2003 Can Patients Contribute to Medical Negligence? Lisa Panique Patients need to be aware that they are fully responsible for disclosing a complete medical history, and physicians may not be liable for damages if they do not comply. Virtual Mentor. 2003;5(4):138-140. doi: 10.1001/virtualmentor.2003.5.4.hlaw1-0304.
Policy Forum Jul 2024 How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice? Ellen L. Edens, MD, MPE, MA, Gabriela Garcia Vassallo, MD, and Robert Heimer, PhD Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD. AMA J Ethics. 2024;26(7):E551-561. doi: 10.1001/amajethics.2024.551.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Viewpoint Jul 2024 Opioid Epidemic Grief and Characterological Harm Reduction Christy A. Rentmeester, PhD Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale. AMA J Ethics. 2024;26(7):E587-590. doi: 10.1001/amajethics.2024.587.
Podcast Jul 2024 Author Interview: "Opioid Epidemic Grief and Characterological Harm Reduction” Dr Christy A. Rentmeester joins Ethics Talk to discuss her article: "Opioid Epidemic Grief and Characterological Harm Reduction.”